Press Releases GENFIT

Equities

GNFT

FR0004163111

Market Closed - Euronext Paris Other stock markets 11:35:13 2024-04-29 am EDT			After market 02:28:55 pm
3.23 ^EUR	+0.62%		3.23	0.00%

Apr. 26	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)	Apr. 25	GL
GENFIT : Extra-Financial Performance Report 2024, 2023 Activity	Apr. 25	PU
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents	Apr. 15	GL
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F	Apr. 05	GL
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update	Apr. 04	GL
GENFIT : Corporate presentation - Investor Events - April 2024	Apr. 03	PU
GENFIT Announces Revenues and Cash Position as of December 31, 2023	Feb. 29	GL
GENFIT Announces Revenues and Cash Position as of December 31, 2023	Feb. 29	AQ
GENFIT Announces 2024 Financial Calendar	Jan. 15	GL
GENFIT Announces 2024 Financial Calendar	Jan. 15	AQ
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial	Jan. 11	GL
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)	Dec. 08	GL
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC	Dec. 07	GL
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials	Dec. 06	GL
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials	Dec. 06	AQ
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023	Nov. 16	GL
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023	Nov. 16	AQ
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine	Nov. 13	GL
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine	Nov. 13	AQ
GENFIT : Document AMF CP. 2023E937612	Nov. 10	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GENFIT

Equities

GNFT

FR0004163111

Press Releases

Filters